Skip to main content
MIT Corporate Relations
MIT Corporate Relations
Search
×
Read
Watch
Attend
About
Connect
MIT Startup Exchange
Search
Sign-In
Register
Search
×
MIT ILP Home
Read
Faculty Features
Research
News
Watch
Attend
Conferences
Webinars
Learning Opportunities
About
Membership
Staff
For Faculty
Connect
Faculty/Researchers
Program Directors
MIT Startup Exchange
User Menu and Search
Search
Sign-In
Register
MIT ILP Home
Toggle menu
Search
Sign-in
Register
Read
Faculty Features
Research
News
Watch
Attend
Conferences
Webinars
Learning Opportunities
About
Membership
Staff
For Faculty
Connect
Faculty/Researchers
Program Directors
MIT Startup Exchange
4.4.23-Health-Weiss
Conference Video
|
Duration: 35:16
April 4, 2023
View this past event
Preview
4.4.23-Health-Weiss
Please
login
to view this video.
Video details
Mammalian synthetic biology has recently emerged as a field that is revolutionizing how we design and engineer biological systems for diagnostic and medical applications. In this talk, we will describe our integrated computational / experimental approach to engineering complex behavior in mammalian cells with applications to Programmable Organoids derived from hiPS cells. In our research, we apply design principles from electrical engineering and other established fields. These principles include abstraction, standardization, modularity, and computer aided design. But, we also spend considerable effort towards understanding what makes synthetic biology different from all other existing engineering disciplines by discovering new design and construction rules that are effective for this unique discipline. We will present Programmable Organoids, a new platform for drug discovery that enables rapid and effective drug screening. Based on programmed differentiation into synthetic mammalian tissues having multiple cell type architectures that are similar to human organs, Programmable Organoids mimic the response of a target organ to both positive and negative effects of drug candidates. Factors that can be non-destructively measured include cell state, viability, and function. Because they are synthetic, Programmable Organoids can host a large array of live-cell biosensors, built-in to one or more cell types, providing a rapid and realtime spatial readout of pathway-specific biomarkers including miRNAs, mRNAs, proteins, and other metabolites. Organoids programmed with both general and disease specific sensors then provide detailed information that can be used to identify candidates for further analysis. We envision a programmable common platform that can be shared among multiple drug candidates.
Locked Interactive transcript
Please
login
to view this video.
Video details
Mammalian synthetic biology has recently emerged as a field that is revolutionizing how we design and engineer biological systems for diagnostic and medical applications. In this talk, we will describe our integrated computational / experimental approach to engineering complex behavior in mammalian cells with applications to Programmable Organoids derived from hiPS cells. In our research, we apply design principles from electrical engineering and other established fields. These principles include abstraction, standardization, modularity, and computer aided design. But, we also spend considerable effort towards understanding what makes synthetic biology different from all other existing engineering disciplines by discovering new design and construction rules that are effective for this unique discipline. We will present Programmable Organoids, a new platform for drug discovery that enables rapid and effective drug screening. Based on programmed differentiation into synthetic mammalian tissues having multiple cell type architectures that are similar to human organs, Programmable Organoids mimic the response of a target organ to both positive and negative effects of drug candidates. Factors that can be non-destructively measured include cell state, viability, and function. Because they are synthetic, Programmable Organoids can host a large array of live-cell biosensors, built-in to one or more cell types, providing a rapid and realtime spatial readout of pathway-specific biomarkers including miRNAs, mRNAs, proteins, and other metabolites. Organoids programmed with both general and disease specific sensors then provide detailed information that can be used to identify candidates for further analysis. We envision a programmable common platform that can be shared among multiple drug candidates.
Locked Interactive transcript
More Videos From This Event
See all videos
April 2023
|
Conference Video
4.4.23-Health-Love
J. Christopher Love
Associate Member, Broad Institute
Associate Member, Ragon Institute of MGH, MIT and Harvard
Raymond A. (1921) and Helen E. St. Laurent Professor of Chemical Engineering, Koch Institute for Integrative Cancer Research
April 2023
|
Conference Video
4.4.23-Health-Roche
Ellen Roche
Latham Family Career Development Professor, MIT Department of Mechanical Engineering
April 2023
|
Conference Video
4.4.23-Health-Shalek
Alex Shalek
Pfizer-Laubach Career Development Associate Professor at MIT
Associate Professor of Chemistry, MIT Department of Chemistry
April 2023
|
Conference Video
4.4.23-Health-Blainey
Paul Blainey
Associate Professor of Biological Engineering, MIT Biological Engineering
April 2023
|
Conference Video
4.4.23-Health-Lieberman
Tami Lieberman
Assistant Professor of Institute for Medical Engineering and Science, Assistant Professor of Civil and Environmental Engineering, MIT Civil and Environmental Engineering
April 2023
|
Conference Video
4.4.23-Health-Kellis
Manolis Kellis
Professor, Computer Science
Head, MIT Computational Biology Group
Associate Member, Broad Institute of MIT and Harvard
Principal Investigator, Computer Science and Artificial Intelligence Lab, MIT Department of Computer Science
April 2023
|
Conference Video
4.4.23-Health-Tadesse
Loza Tadesse
Brit (1961) & Alex (1949) d’Arbeloff Career Development Professor in Mechanical Engineering, MIT Department of Mechanical Engineering
April 2023
|
Conference Video
4.4.23-Health-DxLab
Ho-Jun Suk
Co-Founder & CEO, DxLab
April 2023
|
Conference Video
4.4.23-Health-Ketryx
Erez Kaminski
Founder and CEO, Ketryx Corporation
April 2023
|
Conference Video
4.4.23-Health-Vivtex
Maureen Deehan
Chief Executive Officer, Vivtex
April 2023
|
Conference Video
4.4.23-Health-Tiba-Biotech
Jasdave S. Chahal
Co-Founder and Chief Scientist, Tiba Biotech
April 2023
|
Conference Video
4.4.23-Health-Stratagen-Bio
Greg Ekchian
Co - founder and CEO, Stratagen Bio
April 2023
|
Conference Video
4.4.23-Health-4M-Therapeutics
Benjamin C. Williams
VP of Corporate Development & Co-Founder , 4M Therapeutics
April 2023
|
Conference Video
4.4.23-Health-Decoy-Therapeutics
Rick Pierce
CEO, Decoy Therapeutics
April 2023
|
Conference Video
4.4.23-Health-Replay-Holdings
Matt Mulvey
SVP and Chief Technology Officer, Replay Holdings
April 2023
|
Conference Video
4.4.23-Health-Sunflower-Therapeutics
Laura Crowell
Director of R&D, Sunflower Therapeutics
April 2023
|
Conference Video
4.4.23-Health-Gootenberg-Abudayyeh
Jonathan Gootenberg
Fellow, MIT McGovern Institute
Omar O. Abudayyeh
Fellow, MIT McGovern Institute